SAB BIO Secures $175M to Revolutionize Type 1 Diabetes Treatment with Cutting-Edge Immunotherapy

SAB BIO, a pioneering clinical-stage biopharmaceutical company, is thrilled to announce that it has secured $175,000,000 in a recent funding round—a milestone that will significantly propel its mission to innovate and transform treatment options for type 1 diabetes (T1D). The company, renowned for its novel immunotherapy platform, is in the advanced stages of developing fully-human anti-thymocyte immunoglobulin (hIgG) designed to delay the onset or progression of T1D. This substantial infusion of capital not only underscores the confidence that investors have in SAB BIO’s vision and scientific approach but also provides the critical resources needed to accelerate its research, development, and clinical programs. With this funding, the company is poised to enhance manufacturing capabilities, expand its pipeline, and further refine its clinical trial strategies to ensure that its promising therapy reaches patients in need. SAB BIO is dedicated to addressing the urgency of unmet medical needs that affect those at risk of developing T1D, and this investment marks a pivotal step toward transforming patient care and outcomes. The new capital will facilitate a range of initiatives, from bolstering scientific inquiry with state-of-the-art research infrastructure to deepening collaborations with leading academic institutions and clinical experts. As the journey toward changing the landscape of immunotherapy continues, SAB BIO remains committed to harnessing its innovative technology to make a meaningful impact on the lives of millions affected by T1D worldwide, driving forward with optimism and an unwavering commitment to excellence.